Table 3 Geometric mean and 95% confidence interval for sex hormone concentrations, separately for placebo and active randomization groups for breast cancer cases and controls from the Women’s Health Initiative CEE trial
CEE trial | ||||||
|---|---|---|---|---|---|---|
Placebo | Active treatment | |||||
Cases | Controls | P-value* | Cases | Controls | P-value* | |
Estradiol (pg/ml) | ||||||
Baseline | 12.36 (5.59, 27.38) | 10.56 (4.36, 25.57) | 0.01 | 12.72 (3.88, 41.67) | 10.43 (4.30, 25.32) | 0.01 |
Year 1 | 10.31 (3.55, 29.94) | 9.37 (3.64, 24.14) | 0.21 | 26.47 (7.89, 88.76) | 23.96 (6.77, 84.84) | 0.27 |
Bioavailable estradiol (pg/ml) | ||||||
Baseline | 8.53 (3.41, 21.33) | 6.76 (2.59, 17.65) | 0.001 | 8.74 (2.53, 30.20) | 6.54 (2.27, 18.84) | 0.001 |
Year 1 | 6.99 (2.29, 21.28) | 6.05 (2.21, 16.57) | 0.08 | 12.33 (3.66, 41.57) | 10.21 (3.26, 32.02) | 0.03 |
Estrone (pg/ml) | ||||||
Baseline | 41.05 (17.54, 96.08) | 36.23 (15.48, 84.79) | 0.05 | 41.25 (16.66, 102.15) | 36.44 (15.66, 84.80) | 0.05 |
Year 1 | 38.54 (14.68, 101.17) | 33.70 (12.06, 94.13) | 0.08 | 124.39 (31.09, 497.59) | 134.65 (30.72, 590.11) | 0.44 |
Estrone sulfate (ng/ml) | ||||||
Baseline | 0.86 (0.41, 1.81) | 0.77 (0.33, 1.79) | 0.07 | 0.80 (0.29, 2.20) | 0.77 (0.35, 1.69) | 0.59 |
Year 1 | 0.76 (0.51, 1.49) | 0.62 (0.43, 1.49) | 0.001 | 1.68 (0.65, 6.84) | 1.70 (0.69, 7.06) | 0.94 |
SHBG (Nmol/L) | ||||||
Baseline | 34.11 (14.47, 80.39) | 39.99 (15.30, 104.52) | 0.02 | 34.05 (13.11, 88.43) | 42.79 (15.19, 120.50) | 0.002 |
Year 1 | 34.54 (15.30, 77.95) | 40.86 (15.73, 106.12) | 0.01 | 82.34 (24.57, 276.00) | 99.61 (28.47, 348.54) | 0.03 |